174 related articles for article (PubMed ID: 38694512)
21. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.
Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM
Front Immunol; 2021; 12():742914. PubMed ID: 34659237
[TBL] [Abstract][Full Text] [Related]
22. Neutralizing antibody responses in vaccinated and unvaccinated individuals infected with Omicron BA.1 variant.
Oh SJ; O SW; Choi YJ; Kim JM; Kim D; Kim IH; Park AK; Kim HM; Rhee JE; Jang YR; Yoo CK; Kim JY; Kim EJ
J Clin Virol; 2022 Oct; 155():105253. PubMed ID: 35988369
[TBL] [Abstract][Full Text] [Related]
23. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.
Carreño JM; Alshammary H; Tcheou J; Singh G; Raskin AJ; Kawabata H; Sominsky LA; Clark JJ; Adelsberg DC; Bielak DA; Gonzalez-Reiche AS; Dambrauskas N; Vigdorovich V; ; Srivastava K; Sather DN; Sordillo EM; Bajic G; van Bakel H; Simon V; Krammer F
Nature; 2022 Feb; 602(7898):682-688. PubMed ID: 35016197
[TBL] [Abstract][Full Text] [Related]
24. Immune cell populations and induced immune responses at admission in patients hospitalized with vaccine breakthrough SARS-CoV-2 infections.
Sejdic A; Hartling HJ; Holler JG; Klingen Gjærde L; Lindegaard B; Dungu AM; Gnesin F; Møller MEE; Teglgaard RS; Niemann CU; Brooks PT; Jørgensen CS; Franck KT; Fischer TK; Marquart HV; Harboe ZB; Ostrowski SR
Front Immunol; 2024; 15():1360843. PubMed ID: 38903511
[TBL] [Abstract][Full Text] [Related]
25. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
[TBL] [Abstract][Full Text] [Related]
26. Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron.
Zhu KL; Gao HX; Yao L; Rong J; Yang L; Zhang Z; Jiang P; Duan LJ; Wang GL; Dai EH; Ma MJ
J Infect Dis; 2022 Nov; 226(9):1551-1555. PubMed ID: 35429398
[TBL] [Abstract][Full Text] [Related]
27. Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection.
Goto T; Chong Y; Tani N; Susai N; Yoshinaga T; Sasaki T; Taniguchi M; Kusakabe T; Shimono N; Akashi K; Ikematsu H
Vaccine; 2023 Nov; 41(47):7019-7025. PubMed ID: 37858449
[TBL] [Abstract][Full Text] [Related]
28. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
29. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants.
Servellita V; Syed AM; Morris MK; Brazer N; Saldhi P; Garcia-Knight M; Sreekumar B; Khalid MM; Ciling A; Chen PY; Kumar GR; Gliwa AS; Nguyen J; Sotomayor-Gonzalez A; Zhang Y; Frias E; Prostko J; Hackett J; Andino R; Wadford DA; Hanson C; Doudna J; Ott M; Chiu CY
Cell; 2022 Apr; 185(9):1539-1548.e5. PubMed ID: 35429436
[TBL] [Abstract][Full Text] [Related]
30. Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California.
Servellita V; Morris MK; Sotomayor-Gonzalez A; Gliwa AS; Torres E; Brazer N; Zhou A; Hernandez KT; Sankaran M; Wang B; Wong D; Wang C; Zhang Y; Reyes KR; Glasner D; Deng X; Streithorst J; Miller S; Frias E; Rodgers M; Cloherty G; Hackett J; Hanson C; Wadford D; Philip S; Topper S; Sachdev D; Chiu CY
Nat Microbiol; 2022 Feb; 7(2):277-288. PubMed ID: 35013591
[TBL] [Abstract][Full Text] [Related]
31. TIGIT
Edner NM; Houghton LP; Ntavli E; Rees-Spear C; Petersone L; Wang C; Fabri A; Elfaki Y; Rueda Gonzalez A; Brown R; Kisand K; Peterson P; McCoy LE; Walker LSK
Front Immunol; 2024; 15():1395684. PubMed ID: 38868776
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
[TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.
Torres I; Giménez E; Albert E; Zulaica J; Álvarez-Rodríguez B; Burgos JS; Peiró S; Limón R; Vanaclocha H; Rodado C; Botija P; Sifre A; Tur B; Lozano RA; Orosa I; Vicente-Ruiz M; Carrión RJ; Clari MÁ; Sánchez-Payá J; Díez-Domingo J; Comas I; González-Candelas F; Geller R; Navarro D;
J Med Virol; 2022 Sep; 94(9):4216-4223. PubMed ID: 35585782
[TBL] [Abstract][Full Text] [Related]
34. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection.
Curlin ME; Bates TA; Guzman G; Schoen D; McBride SK; Carpenter SD; Tafesse FG
Med; 2022 Dec; 3(12):827-837.e3. PubMed ID: 36198311
[TBL] [Abstract][Full Text] [Related]
35. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
Hoffmann M; Krüger N; Schulz S; Cossmann A; Rocha C; Kempf A; Nehlmeier I; Graichen L; Moldenhauer AS; Winkler MS; Lier M; Dopfer-Jablonka A; Jäck HM; Behrens GMN; Pöhlmann S
Cell; 2022 Feb; 185(3):447-456.e11. PubMed ID: 35026151
[TBL] [Abstract][Full Text] [Related]
36. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
Elife; 2022 Aug; 11():. PubMed ID: 36004719
[TBL] [Abstract][Full Text] [Related]
37. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.
Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K
Front Immunol; 2022; 13():946318. PubMed ID: 35928813
[TBL] [Abstract][Full Text] [Related]
38. Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination.
Suryawanshi RK; Chen IP; Ma T; Syed AM; Brazer N; Saldhi P; Simoneau CR; Ciling A; Khalid MM; Sreekumar B; Chen PY; Kumar GR; Montano M; Gascon R; Tsou CL; Garcia-Knight MA; Sotomayor-Gonzalez A; Servellita V; Gliwa A; Nguyen J; Silva I; Milbes B; Kojima N; Hess V; Shacreaw M; Lopez L; Brobeck M; Turner F; Soveg FW; George AF; Fang X; Maishan M; Matthay M; Morris MK; Wadford D; Hanson C; Greene WC; Andino R; Spraggon L; Roan NR; Chiu CY; Doudna JA; Ott M
Nature; 2022 Jul; 607(7918):351-355. PubMed ID: 35584773
[TBL] [Abstract][Full Text] [Related]
39. Neutralizing Immunity Induced Against the Omicron BA.1 and BA.2 Variants in Vaccine Breakthrough Infections.
Brazer N; Morris MK; Servellita V; Anglin K; Saldhi P; Garcia-Knight M; Bethancourt S; Sotomayor-Gonzalez A; Wang B; Foresythe A; Nguyen J; Gliwa AS; Pineda-Ramirez J; Sanchez RD; Zhang Y; Ott M; Wadford DA; Andino R; Kelly JD; Hanson C; Chiu CY
J Infect Dis; 2022 Nov; 226(10):1688-1698. PubMed ID: 36134603
[TBL] [Abstract][Full Text] [Related]
40. Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.
Miyamoto S; Suzuki T
Vaccine; 2024 Feb; 42(6):1401-1406. PubMed ID: 38310015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
